• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Iraq Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Iraq Pharmaceuticals and Healthcare Report Q1 2013

  • Published: February 2013
  • Region: Iraq
  • 67 pages
  • Business Monitor International

BMI View

Years of underinvestment have taken their toll on the Iraqi healthcare market, as have international sanctions and deterioration of healthcare infrastructure due to war. Still an unpopular figure on the international market, Iraq’s trade partners are few and far between – although Iraq does have a strong bargaining chip: its oil resources. Healthcare facilities are gradually improving, with plans for new hospitals such as two specialist hospitals planned in partnership with Iran’s Red Crescent organisation. But access to funding is limited, import and exports are restricted, and the country has a severe shortage of trained medical professionals. As such, it is of little surprise that there are few distinctions in the market between OTC and prescription drugs, and counterfeit medicines are rife.

Headline Expenditure Projections

- Pharmaceuticals: IQD1,239bn (US$1.06mn) in 2011 to IQD1,476bn (US$1.26bn) in 2012;
+19.1% in local currency and +19.0% in US dollar terms. Forecast broadly unchanged from Q412.

- Healthcare: IQD9,439bn (US$8.07bn) in 2011 to IQD11,532bn (US$9.86bn) in 2012; +22.1%
in local currency and +22.1% in US READ MORE >

Executive Summary 5

SWOT Analysis 7

Iraq Pharmaceuticals And Healthcare Industry SWOT 7

Iraq Political SWOT 8

Iraq Economic SWOT 8

Iraq Business Environment SWOT 9

Pharmaceutical Business Environment Ratings 10
Table: Pharmaceuticals & Healthcare Q113 Risk/Reward Ratings 10

Rewards 12

Risks 12

Market Summary 14

Regulatory Environment 15

Tendering Procedures 16

Intellectual Property Regime 17

Counterfeit Medicines 17

Pricing Regime 19

Reimbursement Regime 19

Industry Trends and Developments 21

Communicable Diseases 21

Non-Communicable Diseases 22

Healthcare System 23

Healthcare Funding 24

Healthcare System Reform 27

Hospital System 28

Clinical Trials 29

Medical Devices 30

Industry Forecast Scenario 31

Pharmaceutical Market Forecast 31
Table: Pharmaceutical Sales Indicators 2008-2016 33

Healthcare Market Forecast 34
Table: Healthcare Expenditure Indicators 2008-2016 36
Table: Healthcare Governmental Indicators 2008-2016 36
Table: Healthcare Private Indicators 2008-2016 37

Key Growth Factors - Macroeconomic 37
Table: Limited Project Pipeline 38

Pharmaceutical Trade Forecast 40
Table: Exports and Imports Indicators 2009-2016 42

Medical Device Market Forecasts 43
Table: Medical Devices Sales Indicators 2008-2016 44

Other Health Data 44

Key Risks to Forecasts 45

Competitive Landscape 47

Pharmaceutical Industry 47

Recent Pharmaceutical Company Developments 49

Pharmaceutical Distribution 49

Company Profiles 51

Local Companies 51

State Company For Drugs Industry And Medical Appliances - Samarra 51

State Company For Drugs Industries And Medical Appliances - Ninewa 53

Multinational Companies 55

GlaxoSmithKline 55

Demographic Outlook 57

Iraq's Population By Age Group, 1990-2020 ('000) 58

Iraq's Population By Age Group, 1990-2020 (% of total) 59

Iraq's Key Population Ratios, 1990-2020 60

Iraq's Rural And Urban Population, 1990-2020 60

Glossary 61

BMI Methodology 63

How We Generate Our Pharmaceutical Industry Forecasts 63

Pharmaceuticals Risk/Reward Ratings Methodology 64

Ratings Overview 64
Table: Pharmaceutical Business Environment Indicators 65

Weighting 66
Table: Weighting Of Components 66

Sources 66

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos